2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
195
Neoplasm Metastasis
22
Prostatic Neoplasms, Castration-Resistant
20
Breast Neoplasms
19
Neoplasms
18
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Castration-resistant Prostate Cancer
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Carcinoma, Hepatocellular
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Interventions
relacorilant
5
Nutrition Assessment
4
Hydrochlorothiazide
4
Bevacizumab
3
Amlodipine
3
aliskiren
2
Osilodrostat
2
Lisinopril
2
Labetalol
2
Angiotensin-Converting Enzyme Inhibitors
2
Adrenalectomy
2
ziprasidone
1
sacubitril and valsartan sodium hydrate drug combination
1
pembrolizumab
1
pazopanib
1
lutetium Lu 177 dotatate
1
ganirelix
1
gallium Ga 68 dotatate
1
fimasartan
1
enzalutamide
1
clevidipine
1
cediranib
1
bicalutamide
1
benazepril
1
Zolpidem
1
Warfarin
1
Vitamin D
1
Vecuronium Bromide
1
Vancomycin
1
Urine Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hypertension
×
enzalutamide
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled